Aplastic anemia is a condition in which the bone marrow produces an insufficient number of new blood cells. In this study, patients with severe aplastic anemia were given a bone marrow transplant from a compatible family member and followed to track the occurrence of survival and graft-versus-host disease (GVHD). GVHD is a common complication of bone marrow transplantation in which the immune cells produced by the new bone marrow recognize the recipient as a foreign body and mount an attack. To ward off GVHD, the recipients received one of two drug combinations: methotrexate (MTX) or methotrexate plus cyclosporine (MTX+CSP). The goal of the study is to determine whether treatment affected the occurrence of GVHD as well as its impact on survival.
Trt: Treatment group (MTX, MTX+CSP)Time_gvhd: Time on study with respect to GVHD (days)Status_gvhd: Event indicator for GVHD (1=GVHD, 0=No observed GVHD while on study)Time: Time on study with respect to survival (days)Status: Event indicator for GVHD (1=Died, 0=Death not observed during study)Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, and Hansen J (1986). Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood, 68: 119-125.